PeptideStack
5.2kquestions
20kanswers
220users

Is tirzepatide at 2.5 mg/mL stable enough for four weeks of multi-withdrawal use?

Asked 11 May 2025Modified 11 months agoViewed 25k times
23

For reference: tirzepatide · 2.5 mg/mL · four weeks.

Somebody stated this to me confidently and I would like to check it before repeating it.

I would accept a well-reasoned negative answer over a poorly sourced positive one.

What would count as evidence here, and does it exist?

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
bacteriostatic-water
bacteriostatic-water

Water for injection containing roughly 0.9 per cent benzyl alcohol as a bacteriostatic agent. It suppresses growth in a multiple-withdrawal vial;…

149 questions
shelf-life
shelf-life

How long a preparation remains within specification: labelled expiry for a sealed lyophilised vial, beyond-use dating after reconstitution, and…

327 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
shareeditfollowflag
TA
askedtess_amankwah22k2711 May 2025

3 Answers

Accepted answer first, then by votes
62

Accepted answer

four weeks is 28 days and, on a weekly schedule, 4 stopper punctures out of one vial at 2.5 mg/mL. Set the chemical question aside for a moment, because the puncture count is the one with a convention attached: 28 days is 1 times the twenty-eight days conventionally allowed for a preserved multi-dose preparation once it has been entered. Chemically, 2.5 mg/mL is high enough that adsorption to the glass is a rounding error and low enough that it is not protecting you from anything. What 4 withdrawals do add is 4 opportunities to introduce air, 4 coring events on the same stopper, and a headspace that grows with every draw — none of which show up on a certificate and all of which are avoided by splitting into aliquots at reconstitution.

The short version: water enables most of it, oxygen enables oxidation, surfaces enable adsorption, and agitation enables aggregation.

Hydrolysis cleaves the backbone, most readily at aspartate-proline and aspartate-glycine sequences, and is acid-catalysed. In a dry solid it barely proceeds at all.

Degradation pathway by condition

PathwayDominant whenDetected by
DeamidationSolution, neutral to alkaline pHRP-HPLC, +1 Da on MS
OxidationLight, trace metals, peroxidesRP-HPLC, +16 Da on MS
HydrolysisSolution, extremes of pHRP-HPLC, fragment masses
AggregationAgitation, interfaces, high concentrationSEC, visual haze; often invisible on RP-HPLC
Freeze-concentration damageFreeze-thaw of buffered solutionSEC, loss of recovered content

More usefully, oxidation targets methionine, cysteine and tryptophan, adding sixteen daltons per oxygen. It is catalysed by trace metals and promoted by dissolved oxygen and by light.

Deamidation via the succinimide intermediate is well characterised, with sequence-dependent rates highest for asparagine-glycine motifs.

Cold, dry, dark, still. Those four words cover most of the mitigation.

shareimprove this answerflag
TV
answered · acceptedten_mg_vial31k13813 Aug 2025
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
25

Answering this needs the physical state, since a dry powder is protected from most of these and a solution is protected from none.

Light exposure matters for tryptophan-containing sequences and for anything with a chromophore. Amber vials and a closed box are free mitigations.

Aggregation is physical: peptides unfold at air-liquid interfaces and associate. Shaking maximises that interface, which is why swirling and shaking produce visibly different outcomes on the same vial.

Aggregation at air-liquid interfaces is established from surface-tension and particle-count studies and is the basis for anti-agitation handling guidance.

Sequence decides which pathways are even available. Check the residues.

edited 15 Aug 2025 by laminar_bench — fixed an arithmetic slip in the third paragraph

shareimprove this answerflag
LB
answeredlaminar_bench69k572 Aug 2025
17

The relevant point is that a mass shift of plus one dalton is deamidation and plus sixteen is oxidation, so degradation is often visible in a mass spectrum if anyone looks.

Deamidation converts asparagine or glutamine to the corresponding acid via a succinimide intermediate, adding one dalton. It is base-catalysed, accelerates above neutral pH and is the dominant aqueous pathway for many peptides.

Freeze-thaw cycling drives aggregation through concentration at the ice interface and pH shifts as buffer components crystallise out at different rates. Each cycle costs something.

Adsorption losses at low concentrations are quantified in formulation studies and are the reason carrier proteins are used in dilute preparations.

At dilute concentrations, suspect adsorption before you suspect chemistry.

shareimprove this answerflag
LT
answeredlane_transit60k4722 Jul 2025
5Adding for future readers: the domestic leg after delivery is the part you control. – claudia_ferrante 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.